Expert Opinion on Drug Safety
Journal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | 3.0 | Q2 | 52.8% | 0.860 | Q2 | 79.6% |
| 2024 | 3.1 | Q2 | 62.3% | 0.785 | Q2 | 77.3% |
| 2023 | 3.0 | Q2 | 62.5% | 0.905 | Q1 | 83.0% |
| 2022 | 3.1 | Q3 | 55.0% | 0.773 | Q2 | 79.6% |
| 2021 | 4.0 | Q2 | 67.9% | 0.882 | Q1 | 83.7% |
| 2020 | — | — | 1.086 | Q1 | 87.1% | |
| 2019 | — | — | 0.975 | Q1 | 85.2% | |
| 2018 | — | — | 1.007 | Q1 | 84.3% | |
Impact history
Annual SJR and Impact Factor trend.
SJRIF
Journal record
eISSN
1744-764X
ISSN
1474-0338
region
Western Europe
coverage
2002-2026